Theme
Biotech '25: Commercial / Late Stage☆
APLS-26.05%20.0%
ARQT+22.94%20.0%
CYTK+21.36%20.0%
HALO+52.57%20.0%
SPRY-60.12%20.0%
As of Oct 2, 2026, 9:55 PM ET
Biotech '25: Commercial / Late Stage Constituents
Apellis Pharmaceuticals, Inc.APLS | 20.0% | 0.00% | 0.00% | 0.00% | 0.00% | -31.97% | -18.46% | -25.70% | -26.05% | -39.09% | -49.12% | $2.19B |
Arcutis Biotherapeutics, Inc.ARQT | 20.0% | -0.51% | -5.96% | 9.54% | 3.30% | -10.04% | -3.13% | 57.38% | 22.94% | 147.27% | -0.20% | $3.15B |
ARS Pharmaceuticals, Inc.SPRY | 20.0% | -1.21% | -8.48% | -29.55% | -0.49% | -64.81% | -55.82% | -68.58% | -60.12% | -70.93% | -65.12% | $404.2M |
Cytokinetics, IncorporatedCYTK | 20.0% | -0.03% | 1.12% | -4.98% | 4.16% | 7.57% | 9.85% | 69.81% | 21.36% | 17.75% | 78.55% | $8.16B |
Halozyme Therapeutics, Inc.HALO | 20.0% | 2.73% | -4.99% | -0.26% | 2.28% | 62.53% | 57.31% | 73.56% | 52.57% | 81.80% | 169.60% | $13.03B |
| Theme return | — | 0.20% | -3.66% | -6.66% | 0.71% | -13.54% | -6.56% | 16.89% | 0.54% | 22.40% | 83.80% | — |
| Average | 20.0% | 0.20% | -3.66% | -5.05% | 1.85% | -7.34% | -2.05% | 21.29% | 2.14% | 27.36% | 26.74% | $5.39B |
| Median | 20.0% | -0.03% | -4.99% | -0.26% | 2.28% | -10.04% | -3.13% | 57.38% | 21.36% | 17.75% | -0.20% | $3.15B |
| Std Dev | 0.0% | 1.34% | 3.65% | 13.13% | 1.82% | 42.48% | 36.95% | 57.75% | 40.04% | 79.39% | 87.19% | $4.61B |
| Min | 20.0% | -1.21% | -8.48% | -29.55% | -0.49% | -64.81% | -55.82% | -68.58% | -60.12% | -70.93% | -65.12% | $404.2M |
| Max | 20.0% | 2.73% | 1.12% | 9.54% | 4.16% | 62.53% | 57.31% | 73.56% | 52.57% | 147.27% | 169.60% | $13.03B |
| % Positive Tickers | 20.00% | 20.00% | 20.00% | 60.00% | 40.00% | 40.00% | 60.00% | 60.00% | 60.00% | 40.00% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondaryWgt ↓ · Scroll right · Tap headers to sort